KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Leases: 2019

Historic Current Leases for Supernus Pharmaceuticals (SUPN) over the last 1 years, with Dec 2019 value amounting to $2.8 million.

  • Supernus Pharmaceuticals' Current Leases was N/A to $3.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $2.8 million for FY2019, which is N/A change from last year.
  • As of FY2019, Supernus Pharmaceuticals' Current Leases stood at $2.8 million.
  • Over the past 5 years, Supernus Pharmaceuticals' Current Leases peaked at $2.8 million during FY2019, and registered a low of $2.8 million during FY2019.
  • For the 1-year period, Supernus Pharmaceuticals' Current Leases averaged around $2.8 million, with its median value being $2.8 million (2019).